1. Medicines
  2. Cardio-Metabolic
  3. ENTRESTO® (sacubitril/valsartan)

Prescribing information

 

Entresto® (sacubitril/valsartan)

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

For patients living with chronic heart failure, time is essential, so start with ENTRESTO (sacubitril/valsartan)1–3

 

Icon of a person with a stethoscope, with text underneath 'for newly diagnosed chronic HFrEF patients'.

For newly diagnosed
chronic HFrEF patients...
 

LEARN MORE
 

Icon of a person with a medicine bottle, with text underneath 'and for previously diagnosed patients who are ACEi/ARB-naive'

...and for previously diagnosed
patients who are ACEi/ARB-naive
 

LEARN MORE
 

Image of a heart with 'Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring' - Burden of heart failure , text next to it.

Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring4

BURDEN OF
HEART FAILURE
 
 

Image of a heart with 'ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation', text next to it - mode of action.

ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation5

MODE OF
ACTION
 
 

Image of a hospital with 'Change the disease trajectory in chronic HFrEF' text next to it - disease trajectory.

Change the disease trajectory in chronic HFrEF‌1,2,5–14

DISEASE
TRAJECTORY
 
 

Image of a graph with 'Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)' text next to it - Improvements in quality of life.

Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)7,10

IMPROVEMENTS IN
QUALITY OF LIFE
 
 

Image of a shield with 'National guidelines support ENTRESTO as a 1st line treatment option in chronic HFrEF' text next to it - guidelines.

National guidelines support ENTRESTO as a 1st line treatment option in chronic HFrEF1,2,15,16

GUIDELINES
 
 

 

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.5

Please click here for safety information

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; HFrEF, heart failure with reduced ejection fraction; MoA, mode of action.

References:

  1. CaReMe UK HF algorithm. Available at: https://www.britishcardiovascularsociety.org/__data/assets/powerpoint_do.... (Accessed September 2021).
  2. Maddox TM, et al. J Am Coll Cardiol 2021;77(6):772–810.
  3. Ponikowski P, et al. ESC Heart Fail 2014;1(1):4–25.
  4. Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
  5. ENTRESTO Summary of Product Characteristics. Electronic medicines compendium website, UK. Available at: https://www.medicines.org.uk/emc/product/7751/smpc. (Accessed September 2021).
  6. Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
  7. Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
  8. McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
  9. Solomon SD, et al. JACC Heart Fail 2016;4(10):816–822.
  10. Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
  11. Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
  12. Desai AS, et al. JAMA 2019;322(11):1077–1084.
  13. Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
  14. Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.
  15. Welsh HF Expert Reference Group 2021. HF in Wales in 2021 – a Parallel Approach.
  16. Heart Failure Hub Scotland guidelines. Available at: https://www.heartfailurehubscotland.co.uk/wp-content/uploads/2020/03/NHS.... (Accessed September 2021).
Rate this content: 
Average: 4.2 (23 votes)
UK | October 2021 | 145880
Cardio-metabolic
Product
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]